After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Tarrytown-based Regeneron Pharmaceuticals recorded nearly $3.5 billion in revenue in the fourth quarter of 2023, a 1% uptick from the fourth quarter of 2022, the company announced Friday. The company ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

A Regeneron Pharmaceuticals drug that lowers levels of a disease-driving protein has met the goals of a pivotal test in the rare disease generalized myasthenia gravis. Based on these results, ...

U.S. District Judge Sue Robinson of Delaware on Jan. 5 granted Amgen’s request for a permanent injunction to block Sanofi and Regeneron Pharmaceuticals from marketing its cholesterol drug Praluent, ...

NEW YORK, Dec 12 (Reuters) - The chief executive officer of Regeneron Pharmaceuticals Inc on Wednesday said the company is interested in widening its focus to possible treatments for cardiovascular ...